Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.

Phillips AC, Boghaert ER, Vaidya KS, Falls HD, Mitten MJ, DeVries PJ, Benatuil L, Hsieh CM, Meulbroek JA, Panchal SC, Buchanan FG, Durbin KR, Voorbach MJ, Reuter DR, Mudd SR, Loberg LI, Ralston SL, Cao D, Gan HK, Scott AM, Reilly EB.

Mol Cancer Ther. 2018 Apr;17(4):795-805. doi: 10.1158/1535-7163.MCT-17-0710. Epub 2018 Feb 26.

2.

The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors.

Boghaert ER, Lu X, Hessler PE, McGonigal TP, Oleksijew A, Mitten MJ, Foster-Duke K, Hickson JA, Santo VE, Brito C, Uziel T, Vaidya KS.

Neoplasia. 2017 Sep;19(9):695-706. doi: 10.1016/j.neo.2017.06.004. Epub 2017 Aug 5.

3.

A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor.

Vaidya KS, Oleksijew A, Tucker LA, Pappano WN, Anderson MG, Grinnell CM, Zhang Q, Heighton SJ, Mitten MJ, Mishra S, Palma JP, Wang J, Reilly EB, Boghaert ER.

Pharmacology. 2017;100(5-6):229-242. doi: 10.1159/000478663. Epub 2017 Jul 26.

PMID:
28743107
4.

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.

Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB.

Mol Cancer Ther. 2016 Apr;15(4):661-9. doi: 10.1158/1535-7163.MCT-15-0901. Epub 2016 Feb 4.

5.

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.

Mitten MJ, Zipes DP, Maron BJ, Bryant WJ; American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and American College of Cardiology.

Circulation. 2015 Dec 1;132(22):e346-9. doi: 10.1161/CIR.0000000000000251. Epub 2015 Nov 2. Review. No abstract available.

PMID:
26621654
7.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.

PMID:
25787766
8.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, Czabotar PE, Deshayes K, Fairbrother WJ, Flygare JA, Hymowitz SG, Jin S, Judge RA, Koehler MF, Kovar PJ, Lessene G, Mitten MJ, Ndubaku CO, Nimmer P, Purkey HE, Oleksijew A, Phillips DC, Sleebs BE, Smith BJ, Smith ML, Tahir SK, Watson KG, Xiao Y, Xue J, Zhang H, Zobel K, Rosenberg SH, Tse C, Leverson JD, Elmore SW, Souers AJ.

ACS Med Chem Lett. 2014 Aug 26;5(10):1088-93. doi: 10.1021/ml5001867. eCollection 2014 Oct 9.

9.

Assessment of the 12-lead electrocardiogram as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 years of age): a scientific statement from the American Heart Association and the American College of Cardiology.

Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, Okin PM, Saul JP, Salberg L, Van Hare GF, Soliman EZ, Chen J, Matherne GP, Bolling SF, Mitten MJ, Caplan A, Balady GJ, Thompson PD; American Heart Association Council on Clinical Cardiology; Advocacy Coordinating Committee; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; Council on Quality of Care and Outcomes Research, and American College of Cardiology.

J Am Coll Cardiol. 2014 Oct 7;64(14):1479-514. doi: 10.1016/j.jacc.2014.05.006. Epub 2014 Sep 15. No abstract available.

10.

Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology.

Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, Okin PM, Saul JP, Salberg L, Van Hare GF, Soliman EZ, Chen J, Matherne GP, Bolling SF, Mitten MJ, Caplan A, Balady GJ, Thompson PD; American Heart Association Council on Clinical Cardiology, Advocacy Coordinating Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Surgery and Anesthesia, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, Council on Quality of Care and Outcomes Research, and American College of Cardiology.

Circulation. 2014 Oct 7;130(15):1303-34. doi: 10.1161/CIR.0000000000000025. Epub 2014 Sep 15. No abstract available.

PMID:
25223981
11.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW.

Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.

PMID:
23291630
12.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL, Shoemaker AR, Stewart KD, Djuric SW, Vasudevan A.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7615-22. doi: 10.1016/j.bmcl.2012.10.009. Epub 2012 Oct 11.

PMID:
23103095
13.

Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.

Ackler S, Mitten MJ, Chen J, Clarin J, Foster K, Jin S, Phillips DC, Schlessinger S, Wang B, Leverson JD, Boghaert ER.

Br J Pharmacol. 2012 Oct;167(4):881-91. doi: 10.1111/j.1476-5381.2012.02048.x.

14.

The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.

Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW.

Mol Cancer Ther. 2011 Dec;10(12):2340-9. doi: 10.1158/1535-7163.MCT-11-0415. Epub 2011 Sep 13.

15.

Return-to-play decisions: are they the team physician's responsibility?

Matheson GO, Shultz R, Bido J, Mitten MJ, Meeuwisse WH, Shrier I.

Clin J Sport Med. 2011 Jan;21(1):25-30. doi: 10.1097/JSM.0b013e3182095f92. Review.

PMID:
21200167
16.

Legal issues arising out of blood testing for human growth hormone.

Mitten MJ.

Drug Test Anal. 2009 Sep;1(9-10):434-6. doi: 10.1002/dta.57. No abstract available.

PMID:
20355226
17.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.

Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, Xiao Y, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, Shoemaker AR.

Cancer Chemother Pharmacol. 2010 Oct;66(5):869-80. doi: 10.1007/s00280-009-1232-1. Epub 2010 Jan 23.

PMID:
20099064
18.

Legal liability in covering athletic events.

Quandt EF, Mitten MJ, Black JS.

Sports Health. 2009 Jan;1(1):84-90. No abstract available.

19.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo.

Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, Schlessinger S, Wang B, Chemburkar SR, Bauch J, Tse C, Frost DJ, Fesik SW, Rosenberg SH, Elmore SW, Shoemaker AR.

Mol Cancer Ther. 2008 Oct;7(10):3265-74. doi: 10.1158/1535-7163.MCT-08-0268.

20.

Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.

Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, Oleksijew A, O'Connor JM, Wang B, Frost DJ, Bauch J, Marsh K, Tahir SK, Yang X, Tse C, Fesik SW, Rosenberg SH, Elmore SW.

Clin Cancer Res. 2008 Jun 1;14(11):3268-77. doi: 10.1158/1078-0432.CCR-07-4622.

21.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW.

Cancer Res. 2008 May 1;68(9):3421-8. doi: 10.1158/0008-5472.CAN-07-5836.

22.

Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC; American Heart Association Council on Nutrition, Physical Activity, and Metabolism.

Circulation. 2007 Mar 27;115(12):1643-455. Epub 2007 Mar 12. No abstract available.

PMID:
17353433
23.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.

Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q, Giranda VL.

Mol Cancer Ther. 2005 Jun;4(6):977-86.

24.

An inhibitor of Bcl-2 family proteins induces regression of solid tumours.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH.

Nature. 2005 Jun 2;435(7042):677-81. Epub 2005 May 15.

25.

Task Force 12: legal aspects of the 36th Bethesda Conference recommendations.

Mitten MJ, Maron BJ, Zipes DP.

J Am Coll Cardiol. 2005 Apr 19;45(8):1373-5. Review. No abstract available.

26.

Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases.

Maron BJ, Chaitman BR, Ackerman MJ, Bayés de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, Estes NA 3rd, Araújo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP; Working Groups of the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention; Councils on Clinical Cardiology and Cardiovascular Disease in the Young.

Circulation. 2004 Jun 8;109(22):2807-16. Review.

PMID:
15184297
27.

Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.

Beebe X, Yang F, Bui MH, Mitten MJ, Ma Z, Nilius AM, Djuric SW.

Bioorg Med Chem Lett. 2004 May 17;14(10):2417-21.

PMID:
15109624
28.

Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae.

Swords WE, Moore ML, Godzicki L, Bukofzer G, Mitten MJ, VonCannon J.

Infect Immun. 2004 Jan;72(1):106-13.

29.

Criminal consequences of commotio cordis.

Maron BJ, Mitten MJ, Greene Burnett C.

Am J Cardiol. 2002 Jan 15;89(2):210-3. Review. No abstract available.

PMID:
11792344
30.

Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

Mitten MJ, Meulbroek J, Nukkala M, Paige L, Jarvis K, Oleksijew A, Tovcimak A, Hernandez L, Alder JD, Ewing P, Or YS, Ma Z, Nilius AM, Mollison K, Flamm RK.

Antimicrob Agents Chemother. 2001 Sep;45(9):2585-93.

31.

Legal issues affecting medical clearance to resume play after mild brain injury.

Mitten MJ.

Clin J Sport Med. 2001 Jul;11(3):199-202.

PMID:
11495326
32.

Competitive athletes with cardiovascular disease--the case of Nicholas Knapp.

Maron BJ, Mitten MJ, Quandt EF, Zipes DP.

N Engl J Med. 1998 Nov 26;339(22):1632-5. No abstract available.

PMID:
9828254
33.
34.

Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies.

Alder JD, Ewing PJ, Mitten MJ, Oleksijew A, Tanaka SK.

Am J Gastroenterol. 1996 Nov;91(11):2347-54.

PMID:
8931416
35.

When Is Disqualification From Sports Justified?

Mitten MJ.

Phys Sportsmed. 1996 Oct;24(10):75-78. doi: 10.1080/00913847.1996.11948036.

PMID:
29287485
36.

When Is Disqualification From Sports Justified? Medical Judgment vs Patients' Rights.

Mitten MJ.

Phys Sportsmed. 1996 Oct;24(10):75-8. doi: 10.3810/psm.1996.10.1333.

PMID:
20086947
37.

Model of Streptococcus pneumoniae meningitis in adult rats.

Strake JG, Mitten MJ, Ewing PJ, Alder JD.

Lab Anim Sci. 1996 Oct;46(5):524-9.

PMID:
8905585
38.

Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association.

Maron BJ, Thompson PD, Puffer JC, McGrew CA, Strong WB, Douglas PS, Clark LT, Mitten MJ, Crawford MH, Atkins DL, Driscoll DJ, Epstein AE.

Circulation. 1996 Aug 15;94(4):850-6. No abstract available.

PMID:
8772711
39.

Athletic participation with a contagious blood-borne disease.

Mitten MJ.

Clin J Sport Med. 1995 Jul;5(3):153-4. No abstract available.

PMID:
7670969
40.

Legal considerations in treating the injured athlete.

Mitten MJ, Mitten RJ.

J Orthop Sports Phys Ther. 1995 Jan;21(1):38-43.

PMID:
7889031
41.

HIV-Positive Athletes.

Mitten MJ.

Phys Sportsmed. 1994 Oct;22(10):63-8. doi: 10.1080/00913847.1994.11710502.

PMID:
27415173
42.
43.

Ethical, legal, and practical considerations impacting medical decision-making in competitive athletes.

Maron BJ, Brown RW, McGrew CA, Mitten MJ, Caplan AL, Hutter AM Jr.

Med Sci Sports Exerc. 1994 Oct;26(10 Suppl):S230-7. Review. No abstract available.

PMID:
7934744
45.

Ethical, legal and practical considerations affecting medical decision-making in competitive athletes.

Maron BJ, Brown RW, McGrew CA, Mitten MJ, Caplan AL, Hutter AM Jr.

J Am Coll Cardiol. 1994 Oct;24(4):854-60. Review. No abstract available.

Supplemental Content

Loading ...
Support Center